1. Fast up-dosing with a birch allergoid is safe and well tolerated in allergic rhinitis patients with or without asthma.
- Author
-
Zielen S, Plückhahn K, Akboga Y, Rieker-Schwienbacher J, Thieme U, and Rosewich M
- Subjects
- Adolescent, Adult, Allergoids adverse effects, Drug Administration Schedule, Female, Humans, Immunoglobulin G blood, Injections, Subcutaneous, Male, Middle Aged, Patient Compliance, Safety, Young Adult, Allergoids administration & dosage, Betula immunology, Desensitization, Immunologic adverse effects, Desensitization, Immunologic standards, Rhinitis, Allergic, Seasonal prevention & control
- Abstract
Aim: Subcutaneous immunotherapy is effective in treating allergic rhinoconjunctivitis and asthma, but is still inconvenient when heavy schedules are used. A faster dose escalation is desirable., Materials & Methods: In this open-label, Phase II trial, 130 adults were randomized 1:1 to receive a birch pollen allergoid subcutaneous immunotherapy. Group I with four weekly injections and Group II with seven weekly injections. Safety, tolerability and immunogenicity were assessed., Results: Mild-to-moderate treatment-related adverse events were reported for 57.7% of the patients (Group I: 36, Group II: 39). Tolerability was assessed by physicians and rated as 'good' or 'very good' for 55 patients in Group I (87.3%) and for 63 patients in Group II (94.0%). Levels of IgG and IgG
4 increased before and after treatment significantly (p < 0.0001) in both groups., Conclusion: Standard versus fast dose escalation is comparable in terms of safety and tolerability.- Published
- 2019
- Full Text
- View/download PDF